Cerebration improver

Details Cerebration improver Cerebration improver

1999-01-12

2000-09-12

Weddington, Kevin E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

514558, 514560, A61K 31685, A61K 3120

Patent

active

061178535

ABSTRACT:
A cerebration improver having a prominent action for increasing brain glucose level has an effect of improving the cerebration of a subject administered with the improver. The cerebration improver contains as the effective ingredient phosphatidyl-L-serine, or lysophosphatidyl-L-serine produced by eliminating the fatty acid chain at the position .alpha. or .beta. of phosphatidyl-L-serine, or the salts thereof. The phosphatidyl-L-serine has a structural fatty acid chain derived from at least one raw material lecithin selected from the group consisting of soy bean lecithin, rapeseed lecithin or egg yolk lecithin. Using the raw material lecithin as the substrate, phosphatidyl-L-serine can be produced by utilizing transphosphatidylation.

REFERENCES:
patent: 4385053 (1983-05-01), Reisberg et al.
patent: 5001117 (1991-03-01), Hirsch
A. Zanotti et al., "Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats", Psychopharmacology, (1989) 99:316-321.
P.J. Delwaide et al., "Double-blind randomized controlled study of phosphatidylserine in senile demented patients", Acta Neurol. Scand., vol. 73, 1986, pp. 136-140.
Rolf R. Engel, Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzeheimer type, European Neuropsychopharmacology, 2 (1992), pp. 149-155.
T. Cenacchi et al., "Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration", Aging Clin. Exp. Res., 5, 1993, pp. 123-133.
Hyeun Wook Chang et al., "Stereoselective effects of lysophosphatidylserine in rodents", Br. J. Pharmacol., (1988), 93, pp. 647-653.
A. Bruni et al., "Pharmacological effects of phosphatidylserine liposomes", Nature, vol. 260, 1976, pp. 331-333.
Database WPI, Section Ch, Week 8927, Derwent Publications Ltd., London, GB; Class B05, AN 89-197154, XP002015464 of JP-A-01 135 720 (EISAI KK), May 29, 1989.
Database WPI, Section Ch, Week 9444, Derwent Publications Ltd., London, GB; Class B05, AN 94-354659, XP002015465 of JP-A-06 279 311 (NIPPON SHOJI KK), Oct. 4, 1994.
Yumiko Tamori-Natori et al, "Metabolism of Lysophosphatidylserine, a Potentiator of Histamine Release in Rat Mast Cells", J. Biochem., vol. 100, No. 3, 1986, pp. 581-590.
E. Bigon et al, "Pharmacological Effects of Phosphatidylserine Liposomes: The Role of Lysophosphatidylserine", BR. J. Pharmacol., vol. 67, 1979, pp. 611-616.
Hyeun Wook Chang et al, "Stereoselective Effects of Lysophosphatidylserine in Rodents", BR. J. Pharmacol., vol. 93, No. 3, 1988, pp. 647-653.
Satoshi Shuto et al, "A Facile One-Step Synthesis of Phosphatidylhomoserines by Phospholipase D-Catalyzed Transphosphatidylation", Chem. Pharm. Bull., vol. 35, No. 1, 1987, pp. 447-449.
Dr. Herbert P. Fiedler, "Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete", 1989, EDITIO CANTOR AULENDORF, pp. 731-732, p. 1059, p. 1119.

Affiliated with

Also associated with

Rating

Cerebration improver does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cerebration improver, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cerebration improver will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-96247